Ethopropazine and benztropine in neuroleptic-induced parkinsonism
- PMID: 33969
Ethopropazine and benztropine in neuroleptic-induced parkinsonism
Abstract
In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients. This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.
Similar articles
-
No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.J Clin Psychiatry. 1995 Apr;56(4):167-70. J Clin Psychiatry. 1995. PMID: 7713856 Clinical Trial.
-
Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.Clin Ther. 1987;9(4):429-33. Clin Ther. 1987. PMID: 2886223 Clinical Trial.
-
Factors related to tardive dyskinesia.Am J Psychiatry. 1979 Jan;136(1):79-82. doi: 10.1176/ajp.136.1.79. Am J Psychiatry. 1979. PMID: 31802
-
Side effects of depot fluphenazines.Adv Biochem Psychopharmacol. 1974;9(0):301-9. Adv Biochem Psychopharmacol. 1974. PMID: 4599435 Review. No abstract available.
-
Drug-induced parkinsonism and other movement disorders.Can J Neurol Sci. 1990 May;17(2):155-62. doi: 10.1017/s0317167100030389. Can J Neurol Sci. 1990. PMID: 2192787 Review.
Cited by
-
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.Bioorg Med Chem Lett. 2019 Dec 15;29(24):126754. doi: 10.1016/j.bmcl.2019.126754. Epub 2019 Oct 28. Bioorg Med Chem Lett. 2019. PMID: 31708262 Free PMC article.
-
Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.Ther Clin Risk Manag. 2022 Dec 20;18:1129-1142. doi: 10.2147/TCRM.S360268. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36573102 Free PMC article. Review.
-
Identification of Potent and Selective Acetylcholinesterase/Butyrylcholinesterase Inhibitors by Virtual Screening.J Chem Inf Model. 2023 Apr 24;63(8):2321-2330. doi: 10.1021/acs.jcim.3c00230. Epub 2023 Apr 3. J Chem Inf Model. 2023. PMID: 37011147 Free PMC article.
-
An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients.Psychopharmacology (Berl). 1984;84(2):282-4. doi: 10.1007/BF00427460. Psychopharmacology (Berl). 1984. PMID: 6150507
-
Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.Psychopharmacology (Berl). 1982;76(3):222-7. doi: 10.1007/BF00432549. Psychopharmacology (Berl). 1982. PMID: 6808540